Fostamatinib

Drug Profile

Fostamatinib

Alternative Names: FosD; Fostamatinib disodium; Fostamatinib sodium; R 985788; R-406/788; R-788; R-935/788; R788 sodium; R935788 sodium; Tamatinib fosdium; Tavalisse

Latest Information Update: 26 Jun 2017

Price : $50

At a glance

  • Originator Rigel Pharmaceuticals
  • Developer AstraZeneca; Duke University Medical Center; Rigel Pharmaceuticals
  • Class Anti-inflammatories; Antianaemics; Antirheumatics; Oxazines; Phosphoric acid esters; Pyridines; Pyrimidines; Small molecules
  • Mechanism of Action B cell inhibitors; Syk kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Immune thrombocytopenic purpura
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preregistration Immune thrombocytopenic purpura
  • Phase II Autoimmune haemolytic anaemia; IgA nephropathy
  • Phase I Graft-versus-host disease
  • Discontinued Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Rheumatoid arthritis; Solid tumours; Systemic lupus erythematosus; T cell lymphoma; Type 1 diabetes mellitus

Most Recent Events

  • 22 Jun 2017 The US FDA assigns PDUFA action date of 17/April/2018 for fostamatinib disodium for Immune thrombocytopenic purpura
  • 19 Jun 2017 The US FDA accepts New Drug Application for fostamatinib disodium for the treatment of chronic Immune thrombocytopenic purpura
  • 27 Apr 2017 Rigel Pharmaceuticals applies for federal registration of Tavalisse™ mark with US Patent and Trademark Office for fostamatinib in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top